Prime Medicine, Inc.
PRME
$3.27
-$0.03-0.91%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.80% | -2.69% | 9.99% | 8.35% | 1.22% |
| Total Depreciation and Amortization | 14.80% | 19.47% | 26.58% | 28.17% | 32.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.65% | 2.19% | 14.14% | -0.64% | 41.23% |
| Change in Net Operating Assets | -100.35% | -117.18% | 1,370.67% | 426.64% | 384.03% |
| Cash from Operations | -50.38% | -32.31% | 40.39% | 49.07% | 45.70% |
| Capital Expenditure | 68.57% | 37.88% | 17.85% | 21.31% | 18.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -123.50% | -237.60% | -220.30% | 443.87% | 1,819.81% |
| Cash from Investing | -130.53% | -258.88% | -244.48% | 301.42% | 1,120.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 262.93% | -18.45% | -18.87% | -70.91% | -71.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -51.61% | -51.61% | -75.81% | -75.81% |
| Cash from Financing | 227.52% | -22.65% | -23.01% | -71.68% | -71.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,537.11% | -184.69% | -162.95% | 97.54% | 95.63% |